3
Announcements
Trials
Browse
Landscape
Status
Enrolling by invitation
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Genitourinary
1
Conditions
Prostatic Neoplasms
1
Lymphoma, B-Cell
1
Leukemia, Myeloid, Acute
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Hematologic Neoplasms
1
Interventions
Educational Status
5
Interviews as Topic
4
Methods
3
Early Intervention, Educational
3
Cisplatin
3
Blood Specimen Collection
3
pembrolizumab
2
Surveys and Questionnaires
2
Standard of Care
2
Nivolumab
2
Music Therapy
2
Magnetic Resonance Imaging
2
Gemcitabine
2
Counseling
2
zilucoplan
1
tislelizumab
1
somapacitan
1
sacituzumab govitecan
1
rozanolixizumab
1
oxycodone-acetaminophen
1
ibrutinib
1
futibatinib
1
fluorodopa F 18
1
erdafitinib
1
enzalutamide
1
enfortumab vedotin
1
dynorphin-converting endopeptidase
1
durvalumab
1
dalpiciclib
1
brexucabtagene autoleucel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Enrolling by invitation
×
Inosine Monophosphate
×
90 days
×
Clear all
NCT07474051
2026-03-16
PERSIST
AvenCell Therapeutics, Inc.
Enrolling by invitation
178 enrolled